Medigen Vaccine Biologics Corp (高端疫苗) on Tuesday said it has begun manufacturing its experimental COVID-19 vaccine, which it hopes to offer once it obtains an emergency use authorization (EUA).
The company has started producing antigens for its vaccine and filling them at a plant in Hsinchu, company spokesperson Leo Lee (李思賢) said by telephone.
“We hope to be able to offer our COVID-19 vaccine immediately after the Food and Drug Administration [FDA] greenlights it,” Lee said, declining to reveal how many doses the company has manufactured.
Photo: Huang Mei-chu, Taipei Times
President Tsai Ing-wen (蔡英文) has said that locally developed COVID-19 vaccines are expected to be available in July.
Medigen is running a phase 2 clinical trial of its experimental vaccine with 3,752 participants, who had been given the second shot by the end of last month, Lee said, adding that it plans to evaluate the drug’s efficacy at the end of this month.
The firm in the middle of next month would submit to health authorities its interim analysis report and hopes to gain the EUA soon, he said.
Asked if it is wise to start production when the FDA might change the vaccine formula, Lee said that the chances of that are slim, as the regulator reviewed the formula after the phase 1 trials.
“We expect two potential conclusions from the regulator’s review next month: pass or fail,” Lee said.
Medigen tested three doses of its vaccine — low, medium and high — in the phase 1 trials, with the medium dose showing the best potential, so the phase 2 trials only use the medium dose, he said.
“Even if the FDA concludes that the medium dose is not strong enough, the formula does not need to be changed, as the issue could be solved by giving people a third shot,” Lee said.
Medigen has not found serious adverse reactions or vaccine-associated enhanced diseases among participants in the phase 2 trials, it said.
An independent data monitoring committee said that its candidate is safe at a meeting on May 8, Medigen said.
The EU and US are nearing an agreement to coordinate on producing and securing critical minerals, part of a push to break reliance on Chinese supplies. The potential deal would create incentives, such as minimum prices, that could advantage non-Chinese suppliers, according to a draft of an “action plan” seen by Bloomberg. The EU and US would also cooperate on standards, investments and joint projects, as well as coordinate on any supply disruptions by countries like China. The two sides are additionally seeking other “like-minded partners” to join a multicountry accord to help create these new critical mineral supply chains, which feed into
Elon Musk’s lieutenants have reached out to chip industry suppliers, including Applied Materials Inc, Tokyo Electron Ltd and Lam Research Corp, for his envisioned Terafab, early steps in an audacious and likely arduous attempt to break into the production of cutting-edge chips. Staff working for the joint venture between Tesla Inc and Space Exploration Technologies Corp (SpaceX) have sought price quotes and delivery times for an array of chipmaking gear, people familiar with the matter said. In past weeks, they’ve contacted makers of photomasks, substrates, etchers, depositors, cleaning devices, testers and other tools, according to the people, who asked not to
Japan approved ￥631.5 billion (US$3.97 billion) in additional subsidies to hasten Rapidus Corp’s entry into the high-stakes artificial intelligence (AI) chipmaking arena, ramping up support for a project widely regarded as a long shot. The capital is intended to bankroll Rapidus’ work for information technology firm Fujitsu Ltd, one of the initial customers that Tokyo hopes would get the signature endeavor off the ground. The new money raises the fees and investments that the government is injecting into the start-up to ￥2.6 trillion by the end of the current fiscal year to March next year, the Japanese Ministry of Economy, Trade and
The founder of Chinese property giant Evergrande Group (恆大集團) has pleaded guilty to charges of fraud and bribery, a court said yesterday, the latest blow for what was once the country’s leading developer. Evergrande’s rise was propelled by decades of rapid urbanization and rising living standards, but in 2020, its access to credit dramatically narrowed when the government introduced curbs on excessive borrowing and speculation. The company defaulted in 2021 after struggling to repay creditors. Founder Xu Jiayin (許家印), 67, known as Hui Ka Yan in Cantonese, was reportedly held by police in 2023, with Evergrande saying he had been subjected to
RSS